hiPSC-CM Monolayer Maturation State Determines Drug Responsiveness in High Throughput Pro-Arrhythmia Screen

André Monteiro da Rocha1,2, Katherine Campbell1, Sergey Mironov1, Jiang Jiang1, Lakshmi Mundada1, Guadalupe Guerrero-Serna1, José Jalife1,3,4 & Todd J. Herron1,2

Human induced pluripotent stem cell derived cardiomyocytes (hiPSC-CMs) offer a novel in vitro platform for pre-clinical cardiotoxicity and pro-arrhythmia screening of drugs in development. To date hiPSC-CMs used for cardiotoxicity testing display an immature, fetal-like cardiomyocyte structural and electrophysiological phenotype which has called into question the applicability of hiPSC-CM findings to the adult heart. The aim of the current work was to determine the effect of cardiomyocyte maturation state on hiPSC-CM drug responsiveness. To this end, here we developed a high content pro-arrhythmia screening platform consisting of either fetal-like or mature hiPSC-CM monolayers. Compounds tested in the screen were selected based on the pro-arrhythmia risk classification (Low risk, Intermediate risk, or High risk) established recently by the FDA and major stakeholders in the Drug Discovery field for the validation of the Comprehensive In vitro Pro-Arrhythmia Assay (CiPA). Here we show that maturation state of hiPSC-CMs determines the absolute pro-arrhythmia risk score calculated for these compounds. Thus, the maturation state of hiPSC-CMs should be considered prior to pro-arrhythmia and cardiotoxicity screening in drug discovery programs.

Over the last decade the International Conference on Harmonization's (ICH) guideline has dictated the type of pre-clinical in vitro assays used to determine cardiotoxicity and pro-arrhythmia liability for drug compounds in development. The S7B ICH guidelines put emphasis on screening compounds early in drug development for I Kr current blockade using heterologous cells that overexpress just the hERG (Kv11.1) potassium channel. Although these guidelines have prevented potentially arrhythmogenic drugs from entering the market, the emphasis on the single ion channel (hERG, IKr) assay without consideration of the integrated multi-channel nature of the human cardiac cell and action potential has most likely led to falsely labelling safe and effective drugs as pro-arrhythmic1,2. Mislabeling compounds in early development phases of drug discovery has led to cessation of development of potentially safe and effective drugs, and thus the pharmaceutical industry and patients are missing out on opportunities for new therapies3. False positive findings for cardiotoxicity and proarrhythmia liability of novel drug candidates may also be due to discordance between a compound's effects in animals and animal cells compared to those in humans4. Ideally pre-clinical cardiotoxicity and pro-arrhythmia screening should be determined using human cardiomyocytes or mechanically and electrically syncytial monolayers of human cardiomyocytes. Alternatively human cardiomyocytes can also be used to form 3-dimensional (3D) tissues5 and the addition of non-myocyte cells in 3D bioengineered human cardiac tissues has been shown to promote more natural growth and maturation6.

Human based pre-clinical cardiotoxicity approaches are currently being developed and validated via collaboration between academic laboratories, federal regulatory agencies and the pharmaceutical industry4,5,6,9. The evolving human based approach for pre-clinical cardiotoxicity is called the Comprehensive in vitro Pro-Arrhythmia Assay (CiPA for short). Human induced pluripotent stem cell derived cardiomyocytes (hiPSC-CMs) are central to

1University of Michigan, Internal Medicine-Cardiology, Center for Arrhythmia Research, Ann Arbor, MI, 48109, USA. 2Frankel Cardiovascular Center, Cardiovascular Regeneration Core Laboratory, University of Michigan, Ann Arbor, MI, 48109, USA. 3Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), 28029, Madrid, Spain. 4CIBER of Cardiovascular Diseases (CIBERCV), ISCIII, Madrid, Spain. Correspondence and requests for materials should be addressed to T.J.H. (email: toddherr@umich.edu)
CiPA as a human model system that may be used in place of the standard hERG assay for pre-clinical cardiotoxicity testing, hiPSC-CMs can be generated in nearly unlimited quantities, can be cryopreserved and are now offered by several commercial vendors. Importantly, hiPSC-CMs possess the complex array of ion channels that make up the cardiac action potential, which offers a naturally integrated system with advantages over heterologous cell systems in which a single ion channel is tested.

However, a limitation of the current state of the field involves the maturity of hiPSC-CMs. Recent publications have relied on extracellular matrix hardness to mature the phenotype of single hiPSC-CMs and purified monolayers of hiPSC-CMs. Yet, the impact that maturation state of hiPSC-CMs has on responsiveness to drug compounds is unclear. Recently, we showed that the maturation state of hiPSC-CMs impacts on the ion channel expression profile and electrophysiological phenotype of human cardiac monolayers. Extracellular matrix mediated maturation of hiPSC-CM monolayers significantly induced expression of mature cardiomyocyte markers including cardiac specific troponin I (cTnI), sodium channel (NaV 1.5), inward rectifier potassium channel (Kir2.1) and connexin43 (Cx43). Furthermore, extracellular matrix mediated maturation induced functionally mature hiPSC-CM monolayers with rapid impulse propagation velocity (up to 50 cm/s), rapid action potential upstroke (up to ~150 V/s) and hyperpolarized resting membrane potential (~−78 mV). In the current study, we have applied extracellular matrix mediated maturation of hiPSC-CM monolayers plated in 96-well plates for high throughput assessment of drug effects on action potential duration using spontaneously beating and electrically paced preparations. Here we generated customized 96-well plates in which half of the monolayers were fetal-like and the other half were mature hiPSC-CMs. Using a subset of CiPA validated compounds classified as low risk (diltiazem and tamoxifen), intermediate risk (cisapride, clozapine, terfenadine) or high risk (bepridil,
doxifluridine, E-4031, quinidine) for causing Torsade de Pointes (TdP) we determined the effect of maturation state on hiPSC-CM monolayer responsiveness. Results indicate that the maturation state of hiPSC-CM monolayers influences the electrophysiological responsiveness and thus should be considered when using hiPSC-CMs as part of CiPA for drug discovery projects.

Methods
Maturation of Commercially Available hiPSC-CM Monolayers. hiPSC-CMs were used from two different commercial sources: Cellular Dynamics International (CDI, Madison WI) and Cellartis (Takara Bio USA). Custom made 96-well plates with inserts of PDMS (Polydimethylsiloxane) were generated essentially as before. PDMS vulcanized silicone transparent sheeting was obtained from SMI (Specialty Manufacturing, Inc, Saginaw, MI) with 40D (D, Durometer or ≈1000 kPa) hardness and 9 mm diameter coverslips were cut out to fit in each well of 96 well plates. PDMS coverslips were manually added to each well of 96 well plates (Corning) and each plate was subsequently sterilized via ethylene oxide sterilization. PDMS coverslips were then matrigel-coated (500 µg/mL, BD Biosciences, San Jose, CA) prior to plating hiPSC-CMs. Thawing and plating of cryopreserved vials of cells into 96-well plates was as essentially described before. Briefly, 5 × 10⁵ cells were plated per well and allowed to form continuous monolayers and maintained in RPMI (Life Technologies) media supplemented with B27 + insulin (Life Technologies). Monolayers were maintained in culture for seven days before

Figure 2. Phenotype analysis of fetal-like and mature hiPSC-CMs. (A) Western blotting for the mature ventricular myocyte marker β-MyHC. Lanes 1–6 are independent monolayers of fetal-like hiPSC-CMs, lanes 7–12 are independent monolayers of mature hiPSC-CMs. Lane 13 is a positive control human ventricular heart homogenate. This represents one blot where each group was loaded on the same gel and antibody incubation performed at the same time. GAPDH signal was used to normalize for any uneven protein loading. MW = molecular weight marker, * Indicates significant difference, P = 0.0014, unpaired t-test. (B) Western blotting for ventricular myosin light chain (MLC2v), loading sequence is similar to panel A, * Indicates significant difference, P = 0.013, unpaired t-test. (C) Spontaneous action potentials recorded using optical mapping (FluoVolt, transmembrane voltage dye) reveal that mature hiPSC-CM monolayers have abbreviated action potential duration 80 (APD₈₀, ms; mature = 291.8 ± 8.8 ms; n = 8 vs. fetal-like = 459.5 ± 24.3 ms; n = 8). * P = 0.00014 unpaired t-test. (D) Electrical pacing also reveals abbreviated action potential duration in the mature hiPSC-CM monolayers. Original recordings of electrically paced (2 Hz) monolayers of fetal-like (black) and mature (red) hiPSC-CMs. APD restitution plots show the quantification at three different frequencies of activation (1 Hz, 1.5 Hz and 2.0 Hz). Mature hiPSC-CMs had abbreviated APD₈₀ at each frequency tested (1.0 Hz: fetal-like APD₈₀ = 548.7 ± 33.8 ms; n = 7 vs. mature APD₈₀ = 441.2 ± 13.3 ms; n = 5) (1.5 Hz: fetal-like APD₈₀ = 451.5 ± 27.5 ms; n = 7 vs. mature APD₈₀ = 353.1 ± 12.8 ms; n = 5) (2.0 Hz: fetal-like APD₈₀ = 371.8 ± 11.3 ms; n = 7 vs. mature APD₈₀ = 308.0 ± 11.3 ms; n = 5). Data expressed as mean ± sem; unpaired t-test significance * P ≤ 0.02.
electrophysiological testing. Immature fetal-like hiPSC-CM monolayers were generated in 96 well plates without the PDMS coverslip inserts. Fetal-like hiPSC-CMs were also plated on matrigel coated plastic bottoms. Confluent monolayer formation was monitored and confirmed using time-lapse microscopy (Incucyte Zoom, Essen Bioscience, Ann Arbor, MI). Figure 1 shows an example of confluent monolayers using CDI cardiomyocytes. hiPSC-CM morphology was quantified using Wheat Germ Agglutinin conjugated to AlexaFluor 594 (WGA, Thermo Fisher Scientific) with subsequent confocal imaging. In each condition (fetal-like and mature hiPSC-CM monolayers) WGA staining was used to quantify the cell area and perimeter and subsequently the circularity of iPSC-CMs within the monolayers was calculated using the equation: Area * π * 4/Perimeter^2. By this equation the circularity of a circle is 1. Further characterization of molecular maturation was performed by Western blotting for ventricular β-myosin heavy chain (β-MyHC, ATCC A4.951 mouse monoclonal antibody) and ventricular myosin light chain 2 (MLC2v, Protein Tech Group) shown in Fig. 2. These antibodies have been used extensively for quantification of myofilament protein expression. For reliable comparison and quantification each group was loaded on the same gel, and probed with the same antibodies on the same membrane. These complete blots which include molecular weight markers and a positive control (Fig. 2A, human cardiac ventricular homogenate, kind gift from Dr. Adam Helms). For each protein the membrane was sectioned according to molecular weight prior to antibody incubation to enable probing for multiple proteins on the same membrane.

Purification and Maturation of hiPSC-CMs Differentiated Using the Small Molecule Approach. In parallel experiments purified hiPSC-CM monolayers were generated in our laboratory using the established BJ-iPSC line, which was derived using mRNA reprogramming.22,23 Pluripotent stem cell experiments were performed with approval of the HPSCRO (Human Pluripotent Stem Cell Research Oversight Committee) of the University of Michigan. iPSCs were maintained in feeder free conditions (on matrigel) in xeno-free iPS Brew Media (Miltenyi Biotec, Germany) with manual marking and picking to remove spontaneous differentiation. Cardiac directed differentiation was initiated by culturing stem cell monolayers in RPMI media supplemented with B27 (-insulin) and the glycogen synthase kinase-3 inhibitor CHIR99021 (12 µM). On day 1 CHIR99021 was removed and cells are cultured in RPMI with B27 (-insulin) until day 3. On day 3 the small molecule Wnt inhibitor IWP4 (5 µM) was added to the cells and not removed until day 5. Days 5–7 the cells are maintained in RPMI with B27 (-insulin). On day 7 the RPMI media was supplemented with B27+ insulin and maintained in this media with daily changes until day 30. On
day 30 of directed differentiation cell cultures were trypsinized and cardiomyocytes were purified using magnetic activated cell sorting to target and deplete non-myocytes from the cell population which resulted in cardiomyocytes enriched to ~98% purity (Miltenyi Biotec, PSC-derived cardiomyocyte isolation kit, human). Purified hiPSC-CMs were plated in 96-well plates for maturation as described above for commercially available cell lines.

**High Content 96-Well Plate Optical Mapping for hiPSC-CM Action Potentials.**

Optical mapping was performed as essentially described recently with slight modification. A schematic of the 96-well plate optical mapping set up is shown in supplemental Fig. 1. In this assay a 96-well plate is positioned below a high speed CCD camera (200 fps, 80 × 80 pixels) on a heating block to enable recording at physiological temperature (37 °C). hiPSC-CM monolayers were loaded with the membrane potential dye called FluoVolt™ which is commercially available (ThermoFisher Scientific, F10488). Blue LED illumination was used and spontaneous or electrically excited action potentials were recorded with the CCD camera via appropriate emission filter (515 nm, green light, Chroma). For calcium flux quantification monolayers were loaded with fluo-4AM (10 µM). In this assay a 6 × 6 array of wells (supplemental Fig. 1C, 36 wells total) in the 96-well plate could be imaged simultaneously to enable rapid dose response data for all compounds using up to six different doses. Post-acquisition data analysis was done using custom software (Scroll) with automated peak detection capability and automated repolarization quantification to determine APD₈₀ (action potential at 80% of repolarization). Supplemental Fig. 2 shows typical action potential recordings and automated peak and repolarization detection. In some experiments electrical pacing was done to control for rate of activations (supplemental Fig. 3). A custom made frame of field stimulation electrodes was engineered to enable electrical pacing to the 6 × 6 array of wells. Supplemental Fig. 4 shows the successful use of electrical pacing to match the rate of activation in multiple wells.

**Compound formulation and application to hiPSC-CM monolayers.**

Compounds were obtained from the SCREEN-WELL® Cardiotoxicity library (Enzo LifeScience Inc., BML-2850–0100) or through Sigma. Compounds obtained from the SCREEN-WELL® library (low risk = diltiazem, tamoxifen; intermediate risk = terfenadine, clozapine, cisapride; high risk = bepridil, quinidine, dofetilide) were diluted in DMSO as 10 mM stock and serially diluted to the indicated concentrations in HBSS (Hank’s Balanced Salt Solution, Gibco)

---

**Figure 4.** Quantification of E-4031 effect on hiPSC-CM fetal-like or mature monolayers. (A) Single pixel recordings of spontaneous action potentials in fetal-like hiPSC-CM monolayers with treatment of indicated concentrations of E-4031. (B) Single pixel recordings of spontaneous action potential in mature hiPSC-CMs with treatment of indicated concentrations of E-4031. (C) Dose response plot showing that maturation state of hiPSC-CMs impacts on spontaneous action potential responsiveness to E-4031. (D) E-4031 dose response data for each condition was fit using the Sigmoidal, Hill, 4 Parameter equation using Sigmaplot software: 

\[ f = y_0 + \frac{a}{(c + x^b)} \]

\[ R^2 = 0.98 \].

Here the drug induced change of absolute APD₈₀ (ΔAPD₈₀) is plotted as a function of dose.
Compounds not on the CiPA list, including amiodarone, nilotinib and doxorubicin also were part of the SCREEN-WELL® Cardiotoxicity library and were handled in the same way. Fluoxetine was obtained from Sigma (fluoxetine HCl-F132) and was diluted in DMSO to make 10 mM stock, then further diluted in HBSS at the indicated concentrations for screening experiments. On the day of experimentation maintenance media was removed from the monolayers, which then were loaded with FluoVolt (per manufacturer protocol in HBSS) and subsequently treated with test compounds diluted in HBSS for 30 min prior to action potential data acquisition. Action potentials were recorded in the presence of each test compound.

Results and Discussion

hiPSC-CM Monolayer Maturation.

Data in Figs 1 and 2 demonstrate maturation of the structural and functional phenotype of hiPSC-CMs following seven days in primary culture. Consistent with previous work mature hiPSC-CMs were larger in cross-sectional area (Fig. 1C), indicative of cellular hypertrophy which occurs as fetal-like cardiomyocytes mature and growth switches from hyperplastic to hypertrophic. In addition, mature hiPSC-CMs were less circular (more rod-shaped) and also had evidence of bi-nucleation compared to fetal-like hiPSC-CMs (Fig. 1D), as described recently. Although bi-nucleation was more apparent in mature monolayers, the frequency of bi-nucleation quantified by flow cytometry is relatively low (~35.24 ± 3.0% in mature monolayers vs 21.68 ± 1.08% in fetal-like monolayers). Myofilament markers of mature ventricular cardiomyocytes (β-MyHC and MLC2v) were elevated in mature hiPSC-CM monolayers (Fig. 2A and B). Functionally mature monolayers had abbreviated action potential duration in spontaneously beating (Fig. 2C) as well as electrically paced CDI hiPSC-CM monolayers (Fig. 2D). The action potential profile of hiPSC-CM monolayers from Cellartis cells could also be abbreviated using the same approach (supplemental Fig. 5).

Maturation state impact on responsiveness to hERG channel blockers.

E-4031. It has been reported that immature hiPSC-CMs rely critically on the hERG channel for action potential repolarization and setting the maximum diastolic potential. We recently showed that mature hiPSC-CMs also express other repolarizing potassium currents such as I_{K1} and that calcium transients of mature hiPSC-CMs are less sensitive to...
hERG blockade with E-4031. Here we have constructed more complete dose response curves to determine the effect of E-4031 to prolong the action potential of fetal-like or mature hiPSC-CM monolayers. Figure 3 shows original recordings in the form of time-space plots (similar to a confocal line scan) of action potentials over several doses of E-4031 in fetal-like (black, panel A) and mature hiPSC-CM monolayers (red, panel B). These time-space plots reveal the prolongation of the action potential duration and also induction of early after depolarizations (EADs; shown as double depolarizations at the largest drug doses) in the fetal-like hiPSC-CM monolayers (panel A). On the other hand, in mature hiPSC-CM monolayers (red, panel B) APD prolongation could be detected at low concentrations but there was much less evidence of EADs. In Fig. 4A, single pixel recordings over time show the differential response to E-4031 based on maturation state of CDI hiPSC-CM monolayers, which was also observed in the BJ-hiPSC-CM purified monolayers generated in our laboratory (supplemental Fig. 6), although using the BJ-hiPSC-CMs EADs could be induced at the highest dose of E-4031. Next, to match pacing frequencies we utilized the custom made electrical pacing frame for 96-well plates to further test the function of mature iCell hiPSC-CM monolayers. Supplemental Fig. 7 shows a similar qualitative result during electrical pacing (1 Hz) where EADs were very apparent in fetal-like monolayers, but not in the mature hiPSC-CM monolayers when each was incubated in the same concentration of dofetilide (100 nM).

**Dofetilide.** Next we determine the effect of hiPSC-CM monolayer maturation state on responsiveness to dofetilide, another specific blocker of the hERG channel. Results are similar to those observed for E-4031 treatment. Figure 5A shows original recordings of spontaneous action potentials of fetal-like or mature hiPSC-CM monolayers over several doses of dofetilide. Similar to the E-4031, the mature hiPSC-CM monolayers responded differently than the fetal-like hiPSC-CM monolayers. From Fig. 5A and B it is apparent that the mature hiPSC-CM monolayers did not have as severe action potential duration prolongation as observed in the fetal-like monolayers. Furthermore, as shown in Fig. 5C, with electrical pacing (1 Hz) action potential duration alternans were apparent in fetal-like monolayers, but not in the mature hiPSC-CM monolayers when each was incubated in the same concentration of dofetilide (100 nM).
Fluoxetine. Fluoxetine is a compound with hERG channel blocking effects as well as other off target ion channel block, including: Nav1.5 and voltage gated calcium channels. We found differential effects of fluoxetine when comparing fetal-like to mature hiPSC-CM monolayers. This is summarized in Fig. 5D and E. Specifically, in fetal-like monolayers we did not detect any APD 80 prolongation, nor alteration of the spontaneous beating frequency at sub-maximal doses (below 10.0 µmol L⁻¹). However, 10.0 µmol L⁻¹ fluoxetine caused quiescence in 100% of fetal-like monolayers tested (8/8). This finding is consistent with a recent report using immature hiPSC-CM monolayers which showed no effect of fluoxetine to prolong the action potential duration, but quiescence at high dose. On the other hand, fluoxetine prolonged the action potential duration in mature monolayers even at the lowest concentration (1.0 nmol L⁻¹), slowed the spontaneous beating rate and did not induce quiescence at any concentration tested. Thus, unlike other compounds tested mature hiPSC-CM monolayers are more sensitive to the effects of fluoxetine to prolong the action potential duration than immature monolayers, although fetal-like monolayers' electrophysiological function was completely inhibited at the highest concentration.

Terfenadine. Terfenadine is an antihistamine compound that also blocks the hERG channel Terfenadine is classified as a compound with intermediate risk to cause QT prolongation of the human ECG. Supplemental Figure 10 shows that fetal-like hiPSC-CM monolayers are more sensitive to terfenadine's effect of prolonging the action potential duration.

Other compounds. Nilotinib. Nilotinib is an anti-cancer kinase inhibitor compound with possible side effects to prolong the QT interval. We tested the effect of nilotinib on hiPSC-CMs and the results are presented in Figs 6 and 7. Figure 6 shows action potential recordings from fetal-like (black traces) and mature hiPSC-CM monolayers (red). In both maturation states APD prolongation was detected, although to a greater extent in the fetal-like monolayers. In Fig. 7 calcium transients were recorded using fluo-4AM loaded monolayers to study the effect of nilotinib on intracellular calcium flux dynamics. Calcium transient duration (CaTD₈₀) was prolonged in the fetal-like hiPSC-CM monolayers compared to the mature monolayers (727.7 ± 20.5 ms vs. 532.4 ± 20.9 ms; n = 4 monolayers per group) at baseline and this difference between groups persisted over the doses of nilotinib tested. The abbreviated calcium transient duration in the mature hiPSC-CM monolayers suggests also a greater degree of maturation of the calcium homeostasis mechanisms that regulate cardiomyocyte calcium flux. These data show the utility of this platform to determine compound effects on intracellular calcium flux as well as action potential duration.

Figure 7. Nilotinib effects on hiPSC-CM intracellular calcium flux. (A) Original recordings of intracellular calcium flux in fetal-like (black) and mature hiPSC-CM monolayers (B, red traces). (C) Nilotinib increased calcium transient duration 80 (CaTD₈₀) in a dose dependent manner. Similar to the APD recorded in Fig. 6, CaTD₈₀ is prolonged in fetal-like compared to mature hiPSC-CM monolayers at each dose of nilotinib tested. *Denotes statistically significant difference between fetal-like and mature hiPSC-CM CaTD₈₀ values; unpaired t-test; n = 4 per dose; P < 0.05.
Amiodarone. Amiodarone is an anti-arrhythmic compound used to treat arrhythmias like ventricular tachycardia and atrial fibrillation due to its effect to prolong the action potential duration. It is a compound with complex multi-channel blocking effects including inward as well as outward currents. Shown in Table 1, amiodarone surprisingly shortened action potential duration in fetal-like hiPSC-CM monolayers. On the other hand, amiodarone had the anticipated effect to prolong the APD in mature hiPSC-CM monolayers. The maturation dependent effects for amiodarone suggest that ion channels necessary to cause APD prolongation may not be present in the fetal-like hiPSC-CM monolayers.

Compound Risk Stratification. The effect of each compound to prolong or shorten the APD of hiPSC-CM monolayers was quantified relative to vehicle control values obtained in each plate. In other words, the APD or CaT& D quantified at each concentration of each compound was divided by the APD or CaT& D quantified for vehicle control wells. Risk score values for each compound are presented in Table 1. Risk score values were quantified for both fetal-like and mature hiPSC-CM monolayers. In most compounds tested the risk score value depended on the maturation state of the hiPSC-CM monolayers. Figure 8A shows the average risk score grouped by CiPA risk category and maturation state. On average the risk score for intermediate and high risk compounds was greater in the fetal-like than in the mature hiPSC-CM monolayers. The dose dependent risk profile for each compound tested using mature hiPSC-CM monolayers is shown in Fig. 8B and provides evidence that risk stratification proposed by the CiPA initiative can be accurately predicted using this HTS platform. Dose dependent risk profiles for unclassified compounds determined using mature hiPSC-CM monolayers are presented in Fig. 8C.
In summary the results of this study show the impact of maturation state of hiPSC-CMs on drug compound responsiveness. Fetal-like hiPSC-CMs appear to be more sensitive to compounds considered to be of intermediate or high risk for causing pro-arrhythmia and APD prolongation. The maturation state of hiPSC-CMs is important to consider when using these cells for pre-clinical pro-arrhythmia and cardiotoxicity screening in drug discovery programs. Furthermore, we have presented a new method for dictating the functional and structural maturation state of hiPSC-CM monolayers. Using this approach, it is possible to test a compound’s effects on either fetal-like or mature human cardiomyocytes and this may add value to pre-clinical toxicity screening by providing a comprehensive examination of drug effects on varying developmental cardiac phenotypes (fetal-like vs. mature adult phenotypes).

**Study Limitations.** E-4031 is the only compound tested in which a full concentration curve was generated and fit to a sigmoidal curve, this was the only compound that yielded a maximal effect at the concentrations tested. The other compounds tested at concentrations up to 10 µM did not reach a maximal effect in all cases; this maximal concentration is well above the EC50 concentration for all compounds used in pre-clinical pro-arrhythmia testing. Nevertheless, these concentrations were sufficient to determine effectiveness of the platform to detect action potential prolongation, a surrogate for pro-arrhythmia. Also, comparison with human adult cardiomyocytes and this may add value to pre-clinical toxicity screening by providing a comprehensive examination of drug effects on varying developmental cardiac phenotypes (fetal-like vs. mature adult phenotypes).

**References**
1. Colatsky, T. et al. The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative — Update on progress. *J. Pharmacol. Toxicol. Methods* **81**, 15–20 (2016).
2. De Ponti, F., Poluzzi, E., Cavalli, A., Recanatini, M. & Montanaro, N. Safety of Non-Antiarrhythmic Drugs that Prolong the QT Interval or Induce Torsade de Pointes. *Drug Safety* **25**, 263–286 (2002).
3. Stockbridge, N., Morganroth, J., Shah, R. R. & Garnett, C. Dealing with Global Safety Issues. *Drug Safety* **36**, 167–182 (2013).
4. Gintant, G., Sager, P. T. & Stockbridge, N. Evolution of strategies to improve preclinical cardiac safety testing. *Nat. Rev. Drug Discov.* **15**, 457–471 (2016).

### Table 1. APD$_{80}$ Prolongation Risk Scores. Values of the maximal effect on APD for each compound, independent of dose. Presented are values calculated for fetal-like monolayers (italic font) or mature monolayers (bold and underline font). In the majority of CiPA classified compounds the values were higher for fetal-like monolayers compared to mature monolayers.

| Compound | Maximum APD$_{80}$ Prolongation Risk Score (Fetal-like hiPSC-CM) | Maximum APD$_{80}$ Prolongation Risk Score (Mature hiPSC-CM) |
|----------|---------------------------------------------------------------|-------------------------------------------------|
| **CiPA: High Risk** | | |
| Bepridil: | — | 1.64 |
| Dofetilide: | 2.14 | 1.81 |
| Quinidine: | 1.91 | 1.81 |
| E-4031: | 3.04 | 2.04 |
| Mean: | 2.36 ± 0.3 | 1.83 ± 0.08 |
| Range: | 1.91–3.04 | 1.64–2.04 |
| **CiPA: Intermediate Risk** | | |
| Ciapride: | 1.49 | 1.15 |
| Clozapine: | 1.14 | 1.33 |
| Terfenadine: | 1.43 | 1.21 |
| Mean: | 1.35 ± 0.10 | 1.23 ± 0.05 |
| Range: | 1.14–1.49 | 1.15–1.33 |
| **CiPA: Low Risk** | | |
| Diltiazem: | 0.97 | 1.03 |
| Tamoxifen: | 1.12 | 1.04 |
| Mean: | 1.05 ± 0.08 | 1.04 ± 0.04 |
| Range: | 0.97–1.12 | 1.03–1.04 |
| **Other Compounds** | | |
| Oncology | | |
| Nilotinib: | 1.36 | 1.29 |
| Doxorubicin: | 1.15 | 1.15 |
| Anti-arrhythmic | | |
| Amiodarone: | 0.91 | 1.34 |
| Anti-depressant | | |
| Fluoxetine: | 1 | 1.28 |
11. Hortigon-Vinagre, M. P. et al. The Use of Ratiometric Fluorescence Measurements of the Voltage Sensitive Dye Di-4-ANEPPS to Examine Action Potential Characteristics and Drug Effects on Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes. *Toxicol. Sci.* 154, 320–331 (2016).

12. Anson, B. D., Kolaja, K. L. & Kamp, T. J. Opportunities for Use of Human iPSC Cells in Predictive Toxicology. *Clin. Pharmacol. Ther.* 89, 754–758 (2011).

13. Ma, J. et al. High purity human-induced pluripotent stem cell-derived cardiomyocytes: electrophysiological properties of action potentials and ionic currents. *Am. J. Physiol. Heart Circ. Physiol.* 301, H2006–H2017 (2011).

14. Li, X. et al. Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling. *Proc. Natl. Acad. Sci. USA* 109, E1848–E1857 (2012).

15. Mummery, C. L. et al. Differentiation of Human Embryonic Stem Cells and Induced Pluripotent Stem Cells to Cardiomyocytes: A Methods Overview. *Circ. Res.* 111, 344–358 (2012).

16. Zhang, J. et al. Extracellular Matrix Promotes Highly Efficient Cardiomyocyte Differentiation of Human Pluripotent Stem Cells: The Matrix Sandwich Method. *Circ. Res.* 111, 1125–1136 (2012).

17. Lee, P. et al. Simultaneous Voltage and Calcium Mapping of Genetically Purified Human Induced Pluripotent Stem Cell–Derived Cardiac Myocyte Monolayers. *Circ. Res.* 110, 1556–1563 (2012).

18. Monteiro da Rocha, A. et al. Deficient cMyBP-C protein expression during cardiomyocyte differentiation underlies human hypertrophic cardiomyopathy cellular phenotypes in disease specific human ES cell derived cardiomyocytes. *J. Mol. Cell. Cardiol.* 99, 197–206 (2016).

19. Yang, X., Pabon, L. & Murry, C. E. Engineering Adolescence: Maturation of Human Pluripotent Stem Cell–Derived Cardiomyocytes. *Circ. Res.* 114, 511–523 (2014).

20. Feaster, T. K. et al. Matrigel Mattress: A Method for the Generation of Single Contracting Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes. *Circ. Res.* 117, 995–1000 (2015).

21. Knollmann, B. C. Induced Pluripotent Stem Cell–Derived Cardiomyocytes. Boutique Science or Valuable Arrhythmia Model? *Circ. Res.* 112, 969 (2013).

22. Herron, T. J. et al. Extracellular Matrix–Mediated Maturation of Human Pluripotent Stem Cell–Derived Cardiac Monolayer Structure and Electrophysiological Function. *Circ. Arrhythm. Electrophysiol.* 9, e003638 (2016).

23. Bizy, A. et al. Myosin light chain 2-based selection of human iPSC-derived early ventricular cardiac myocytes. *Stem Cell Res.* 11, 1335–1347 (2013).

24. Li, X. et al. Directed cardiomyocyte differentiation from human pluripotent stem cells by modulating Wnt5a/catenin signaling under fully defined conditions. *Nat. Protocols* 8, 162–175 (2013).

25. Campbell, K. et al. Spatial gradients in action potential duration created by regional magnetofection of hERG are a substrate for wavebreak and turbulent propagation in cardiomyocyte monolayers. *J. Physiol.* 590, 6363–6379 (2012).

26. Oparil, S., Bishop, S. P. & Clapp, F. J. Jr. Myocardial cell hypertrophy or hyperplasia. *Hypertension (Dallas, Tex.: 1979)* 6, III38–43 (1984).

27. Doss, M. X. Maximum diastolic potential of human induced pluripotent stem cell-derived cardiomyocytes depends critically on I(Kr). *PLoS ONE* 7, e40288 (2012).

28. Rajamani, S. et al. Drug-induced long QT syndrome: hERG K(+) channel block and disruption of protein trafficking by fluoxetine and norfluoxetine. *Br. J. Pharmacol.* 149, 481–498 (2006).

29. Poulin, H. et al. Fluoxetine Blocks Na(V)1.5 Channels via a Mechanism Similar to That of Class 1 Antiarrhythmics. *Mol. Pharmacol.* 86, 378–389 (2014).

30. Deák, F. et al. Inhibition of voltage-gated calcium channels by fluoxetine in rat hippocampal pyramidal cells. *Neuropharmacology* 39, 1029–1036 (2000).

31. Kirchhof, P. et al. Amiodarone-Induced Postrepolarization Refractoriness Suppresses Induction of Ventricular Fibrillation. *J. Pharmacol. Exp. Ther.* 305, 257–263 (2003).

32. Kodama, I., Kamiya, K. & Toyama, J. Cellular electropharmacology of amiodarone. *Cardiovasc. Res.* 35, 13–29 (1997).

**Acknowledgements**

Research reported in this publication was supported by the National Institute of Environmental Health Sciences of the National Institutes of Health under Award Number R43ES027703. This study was also supported by the Lefkofsky Family Foundation (T.J.H.), the UM Frankel Cardiovascular Center (T.J.H.), and the State of Michigan Economic Development Fund (U-M MTRAC), T.J.H. and J.J.). The authors also acknowledge Cellartis for providing cryopreserved cardiomyocytes in-kind (Cellartis® Cardiomyocytes, from ChiPSC22).

**Author Contributions**

A.M.R. generated 96 well plates of hiPSC-CM monolayers, purified hiPSC-CMs, applied drug compounds, performed Western blotting and optical mapping recordings. K.C. generated hiPSC-CM monolayers and analyzed functional data. S.M. designed Scroll software and the automated peak detection and action potential duration features for analysis. J.J. designed, fabricated and validated electrical pacing frames and electrodes for 96 well optical mapping. L.M. performed and analyzed Western blots. G.G.S. performed immunostaining and confocal imaging of monolayers. J.J. provided experimental design, analysis and interpretation of data. T.J.H. designed experimental plan, performed optical mapping recordings, analyzed and interpreted data. T.J.H., A.M.R. and J.J. wrote, revised and edited the manuscript with input from the other authors.
